PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia
The DOI matches its Crossref record; 57 of the 60 references it cites were found in a registry or an index.
Abstract
Targeting B-cell receptor signaling using the PI3Kδ inhibitor idelalisib is a highly effective treatment option for relapsed/refractory chronic lymphocytic leukemia (CLL) patients. In addition to its direct impact on tumor cells, PI3Kδ inhibition can modulate the activity of regulatory T-cells (Tregs) resulting in enhanced anti-tumoral immune functions which may contribute to the success of PI3Kδ inhibitors in cancer therapy. The role of Tregs in CLL and their modulation by PI3Kδ inhibitors was so far poorly understood. Using the Eµ-TCL1 adoptive transfer model of CLL, we show that disease development induces the accumulation of activated and highly immunosuppressive Tregs. Depletion of CD25+ Tregs using anti-CD25 antibodies resulted in enhanced CD8+ T-cell activation, effector differentiation, and functional capacity. We further show that pharmacological inhibition of PI3Kδ effectively controlled disease and significantly decreased both CD25+ and CD25- Treg numbers, proliferation and activation status in CLL-bearing mice. Nonetheless, this PI3Kδ-mediated decrease in Tregs did not translate into better CD8+ T-cell function, as PI3Kδ inhibition concomitantly abrogated T-cell receptor signaling in CD8+ T-cells leading to decreased activation, effector cell differentiation and proliferation. Collectively, these data highlight the strong immunomodulatory effects of PI3Kδ inhibitors in CLL and are of relevance for a rational design of idelalisib-based combination therapies in CLL.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“mice bearing an inactivating mutation in Pik3cd exhibit superior resistance to chronic lymphocytic leukemia (CLL) in the context of impaired TREG cell expansion (Dong et al., 2019; Hanna et al., 2019)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Hanna et al., 2019
Citations
Cites
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Regulatory T cells: mechanisms of differentiation and function
Josefowicz, S. Z., Lu, L.-F., & Rudensky, A. Y. (2012) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141623 · Cited by 2,866
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grünhagen, U., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61381-5 · Cited by 1,888
Self-citationIdelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,710
Self-citationIbrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C., Brown, J. R., O'Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400376 · Cited by 1,639
PI3Kγ is a molecular switch that controls immune suppression
Kaneda, M. M., Messer, K. S., Ralainirina, N., Li, H., Leem, C. J., Gorjestani, S., Woo, G., Nguyen, A. V., Figueiredo, C. C., Foubert, P., et al. (2016) · Nature · doi:10.1038/nature19834 · Cited by 1,173
Moran, A. E., Holzapfel, K. L., Xing, Y., Cunningham, N. R., Maltzman, J. S., Punt, J., & Hogquist, K. A. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110308 · Cited by 1,034
Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice
Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E., Pearce, W., Meek, S. E., Salpekar, A., Waterfield, M. D., et al. (2002) · Science · doi:10.1126/science.1073560 · Cited by 946
Cited by
Yan, Y., Huang, L., Liu, Y., Yi, M., Chu, Q., Jiao, D., & Wu, K. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01322-3 · Cited by 212
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?
Roessner, P. M., & Seiffert, M. (2020) · Leukemia · doi:10.1038/s41375-020-0873-2 · Cited by 144
Self-citationde Weerdt, I., Hofland, T., de Boer, R., Dobber, J. A., Dubois, J., van Nieuwenhuize, D., Mobasher, M., de Boer, F., Hoogendoorn, M., Velders, G. A., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000360 · Cited by 110
Cellular and molecular mechanisms breaking immune tolerance in inborn errors of immunity
Sogkas, G., Atschekzei, F., Adriawan, I. R., Dubrowinskaja, N., Witte, T., & Schmidt, R. E. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00626-z · Cited by 102
Targeting the tumor microenvironment in chronic lymphocytic leukemia
Svanberg, R., Janum, S., Patten, P., Ramsay, A. G., & Niemann, C. U. (2021) · Haematologica · doi:10.3324/haematol.2020.268037 · Cited by 99
“Interestingly, PI3Kδ inhibition in a CLL mouse model resulted in reduced numbers and maturation of Tregs; however, this did not result in enhanced antitumor CD8 T-cell function, likely due to concomitant direct inhibition of PI3Kδ downstream of Tcell receptor signaling.(58) Similar to the effects of ibrutinib, idelali…”
BackgroundImmune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia
Griggio, V., Perutelli, F., Salvetti, C., Boccellato, E., Boccadoro, M., Vitale, C., & Coscia, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594556 · Cited by 74
T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword
Vlachonikola, E., Σταματόπουλος, Κ., & Chatzidimitriou, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.612244 · Cited by 74
EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia
Cid, L. L., Roessner, P. M., Chapaprieta, V., Öztürk, S., Roider, T., Bordas, M., Ízcue, A., Colomer, D., Dietrich, S., Stilgenbauer, S., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01198-1 · Cited by 68
Self-citationRoessner, P. M., Cid, L. L., Lupar, E., Roider, T., Bordas, M., Schifflers, C., Arseni, L., Gaupel, A., Kilpert, F., Krötschel, M., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01136-1 · Cited by 63
Self-citationCurrent Treatment Options in CLL
Bewarder, M., Stilgenbauer, S., Thurner, L., & Kaddu‐Mulindwa, D. (2021) · Cancers · doi:10.3390/cancers13102468 · Cited by 51
“In line with this, in vitro studies suggest that PI3Kδ inhibition decreases the activity of regulatory T cells (Tregs), thus stimulating an anti-tumor immune response [88].”
BackgroundSelf-citationTargeting the PI3K/AKT/mTOR pathway in lung cancer: mechanisms and therapeutic targeting
Qiang, M., Chen, Z., Liu, H., Dong, J., Gong, K., Zhang, X., Huo, P., Zhu, J., Shao, Y., Ma, J., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1516583 · Cited by 66
Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies
Maharaj, K. K., Uriepero, A., Sahakian, E., & Pinilla-Ibarz, J. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.943354 · Cited by 46
PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
Tarantelli, C., Argnani, L., Zinzani, P. L., & Bertoni, F. (2021) · Cancers · doi:10.3390/cancers13215535 · Cited by 40
“demonstrated that PI3Kδ inhibition decreases Tregs numbers, proliferation, and activity in the Eμ-TCL1 model, but also CD8+ effector T-cells numbers and cytotoxicity T-cell ability [94].”
BackgroundRevolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm
Scheffold, A., & Stilgenbauer, S. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0881-4 · Cited by 39
Self-citationMaharaj, K. K., Powers, J. J., Mediavilla-Varela, M., Achille, A. N., Gamal, W. M., Quayle, S. N., Jones, S. S., Sahakian, E., & Pinilla-Ibarz, J. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.590072 · Cited by 36
Phosphatidylinositol 3 Kinase δ Inhibitors
Brown, J. R. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000414 · Cited by 33
Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia
Hofland, T., Eldering, E., Kater, A. P., & Tonino, S. H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174315 · Cited by 31
Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy
Apollonio, B., Ioannou, N., Papazoglou, D., & Ramsay, A. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.626818 · Cited by 31
Jebaraj, B. M. C., Müller, A., Dheenadayalan, R. P., Endres, S., Roessner, P. M., Seyfried, F., Walliser, C., Wist, M., Qi, J., Tausch, E., et al. (2021) · Blood · doi:10.1182/blood.2021011516 · Cited by 28
Self-citationHui, W., Huang, W. J., Zheng, Z., Li, Y., Li, P., & Yang, H. Q. (2023) · Phytotherapy Research · doi:10.1002/ptr.7988 · Cited by 28
“Anti-CD25 antibody (102059, BioLegend, San Diego, CA) was used to deplete Treg cells in vivo, as previously described (Hanna et al., 2019).”
MethodSmall-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies
Cao, X., Jin, X., Zhang, X., Utsav, P., Zhang, Y., Guo, R., Lu, W., & Zhao, M. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01049-4 · Cited by 27
Control of T lymphocyte fate decisions by PI3K signaling
Murter, B., & Kane, L. (2020) · F1000Research · doi:10.12688/f1000research.26928.1 · Cited by 26
Aydin, E., Faehling, S., Saleh, M., Cid, L. L., Seiffert, M., & Roessner, P. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.595818 · Cited by 27
“As suggested by other models, PI3Kd inhibition ex vivo decreased TCR signaling of CD8 T-cells, which were isolated from TCL1-leukemia bearing mice, in a dose-dependent manner (134).”
BackgroundMethodInfluentialSelf-citationLights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia
Visentin, A., Frezzato, F., Severin, F., Imbergamo, S., Pravato, S., Gargarella, L. R., Manni, S., Pizzo, S., Ruggieri, E., Facco, M., et al. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s268899 · Cited by 24
Vitale, C., Boccellato, E., Comba, L., Jones, R., Perutelli, F., Griggio, V., & Coscia, M. (2021) · Cancers · doi:10.3390/cancers13153856 · Cited by 24
“Beside the increased count, Tregs from CLL patients produce a larger amount of IL‐ 10 and TGF‐β1 and overexpress CTLA‐4 compared to healthy controls [33,52,61].”
BackgroundWierzbińska, J. A., Tóth, R., Ishaque, N., Rippe, K., Mallm, J., Klett, L. C., Mertens, D., Zenz, T., Hielscher, T., Seifert, M., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-00724-7 · Cited by 23
Self-citationCombining Oncolytic Viruses and Small Molecule Therapeutics: Mutual Benefits
Spiesschaert, B., Angerer, K., Park, J., & Wollmann, G. (2021) · Cancers · doi:10.3390/cancers13143386 · Cited by 22
Hofland, T., de Weerdt, I., ter Burg, H., de Boer, R., Tannheimer, S., Tonino, S. H., Kater, A. P., & Eldering, E. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900321 · Cited by 21
Homeostatic and pathogenic roles of PI3Kδ in the human immune system
Sogkas, G., Adriawan, I. R., Dubrowinskaja, N., Atschekzei, F., & Schmidt, R. E. (2020) · Advances in immunology · doi:10.1016/bs.ai.2020.02.001 · Cited by 24
Galigalidou, C., Zaragoza‐Infante, L., Iatrou, A., Chatzidimitriou, A., Σταματόπουλος, Κ., & Agathangelidis, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.769612 · Cited by 21
Rohrbacher, L., Brauchle, B., Wagner, A. O., von Bergwelt‐Baildon, M., Bücklein, V., & Subklewe, M. S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.608625 · Cited by 20
“Emerging data from clinical trials suggests that the improved T-cell-mediated antitumor response and the impressive clinical outcome in CLL might be due to reduced Treg numbers and their reduced suppressive function in idelalisib-treated patients (57, 58).”
BackgroundSafety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma
Makita, S., Hosoba, R., & Tobinai, K. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1802424 · Cited by 17
The role of Th17 cells in chronic lymphocytic leukemia: friend or foe?
Gamal, W. M., Sahakian, E., & Pinilla-Ibarz, J. A. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008985 · Cited by 17
Anti-Acute Myeloid Leukemia Activity of CD38-CAR-T Cells with PI3Kδ Downregulation
An, N., Pan, Y., Yang, L., Zhang, Q., Deng, S., Zhang, Q., & Du, X. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00913 · Cited by 15
Roessner, P. M., Hanna, B. S., Öztürk, S., Schulz, R., Cid, L. L., Yazdanparast, H., Scheffold, A., Colomer, D., Stilgenbauer, S., Lichter, P., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16316 · Cited by 18
Self-citationMachado, A. K. D. C., Machado, C. B., Pessoa, F. M. C. D. P., Barreto, I. V., Gadelha, R. B., Oliveira, D. D. S., Ribeiro, R. M., Lopes, G. S., de Moraes, M. O., de Moraes, M. E. A., et al. (2024) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10279 · Cited by 16
Góral, A., Firczuk, M., Fidyt, K., Śledź, M., Simoncello, F., Siudakowska, K., Pagano, G., Moussay, E., Paggetti, J., Nowakowska, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.781364 · Cited by 14
“For instance, the administration of anti-CD25 antibodies or phosphoinositide 3kinase d (PI3Kd) inhibitors affected not only Tregs but also abrogated the activation and function of CD8 lymphocytes (18).”
BackgroundFaehling, S., Coelho, M., Floerchinger, A., Schneider, C., Stilgenbauer, S., Lichter, P., Seiffert, M., & Roessner, P. M. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000840 · Cited by 14
Self-citationGargiulo, E., Teglgaard, R. S., Faitová, T., & Niemann, C. U. (2023) · Acta Haematologica · doi:10.1159/000533234 · Cited by 13
“Idelalisib-associated toxicities are likely linked to inhibition of PI3K δ in T-cell receptor signaling, impairing CD8 + T-cell cytotoxicity but also inhibiting Treg, resulting in impaired immune tolerance [74].”
BackgroundOvercoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma
van Bruggen, J. A. C., Martens, A. W. J., Tonino, S. H., & Kater, A. P. (2020) · Cancers · doi:10.3390/cancers12123837 · Cited by 14
Fındık, V., Gerçik, B. T. V., Sinek, Ö., Erdem, S. S., & Ruiz‐López, M. F. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00569 · Cited by 14
Vitale, C., Griggio, V., Perutelli, F., & Coscia, M. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000988 · Cited by 10
The Non-hodgkin Lymphoma Treatment and Side Effects: A Systematic Review and Meta-analysis
Câmara, A. B., & Brandão, I. A. (2023) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892818666230117151757 · Cited by 7
Bréal, C., Beuvon, F., Witasse-Thezy, T. D., Dermine, S., Franchi, P., Deau, B., Willems, L., Grignano, É., Contejean, A., Bouscary, D., et al. (2023) · Cancers · doi:10.3390/cancers15082279 · Cited by 7
“Hence, Pi3K inhibition decreases the T-regulatory cell number and function [33,34].”
BackgroundExploring the controversial role of PI3K signalling in CD4+ regulatory T (T-Reg) cells
Poli, A., Fiume, R., Mongiorgi, S., Zaurito, A. E., Sheth, B., Vidalle, M. C., Abdul-Hamid, S., Kimber, S. T., Campagnoli, F., Ratti, S., et al. (2020) · Advances in Biological Regulation · doi:10.1016/j.jbior.2020.100722 · Cited by 5
Understanding and Managing Infectious Complications in Chronic Lymphocytic Leukemia
Vainer, N., Katsimigas, A., Rotbain, E. C., & Niemann, C. U. (2025) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2025.05.003 · Cited by 4
Hosseini-Valiki, F., Taghiloo, S., Tavakolian, G., Amjadi, O., Tehrani, M., Hedayatizadeh‐Omran, A., Alizadeh‐Navaei, R., Zaboli, E., Shekarriz, R., & Asgarian‐Omran, H. (2020) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2020.21.9.2615 · Cited by 4
“Chronic lymphocytic leukemia (CLL) is correlated with main defects in T-cell function resulting imparity in antitumor immune responses and enhanced susceptibility to infections (Riches et al., 2013; Hanna et al., 2019).”
BackgroundMakita, S., Ota, S., Mishima, Y. M., Usuki, K., Ennishi, D., Yanada, M., Fukuhara, N., Yamamoto, R., Takamine, A., Nohara, G., et al. (2023) · International Journal of Hematology · doi:10.1007/s12185-023-03689-6 · Cited by 3
“The etiology of immune-mediated AEs is not completely understood; however, it is generally believed that it caused by the effects of PI3K-δ inhibition on regulatory T cells; the abrogation of the immunosuppressive activity of regulatory T cells leading to cytotoxic T-cell organ infiltration [29].”
PI3Kδ Mediates Fibrosis by Patient-Derived Vitreous
Liu, D., Yan, B., Yin, Y., Chen, F., Guo, C., Li, Q., Liu, J., Li, P., Wu, W., & Luo, J. (2024) · Laboratory Investigation · doi:10.1016/j.labinv.2024.102026 · Cited by 3
Targeting PI3Kδ for lymphoma and immune diseases treatment: a review
Jia, W. (2026) · Molecular Diversity · doi:10.1007/s11030-026-11536-z · Cited by 2
Pharmacologic Differentiation of Drugs Targeting the PI 3K‐ AKT ‐m TOR Signaling Pathway
Ahn, I. E., Brown, A. J. R., & Davids, M. S. (2023) · Wiley eBooks · doi:10.1002/9781119819950.ch6
Feng, Z., Luo, X., Tang, L., Long, W. S., He, L., Wang, W., Zhang, K., Xu, H., Li, D., & Wei, B. (2025) · Research Square · doi:10.21203/rs.3.rs-7913208/v1
Wierzbinska, J. A., Toth, R., Ishaque, N., Rippe, K., Mallm, J.-P., Klett, L. C., Mertens, D., Zenz, T., Hielscher, T., Seifert, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12004518
Self-citationWierzbinska, J. A., Toth, R., Ishaque, N., Rippe, K., Mallm, J.-P., Klett, L. C., Mertens, D., Zenz, T., Hielscher, T., Seifert, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12004509
Self-citationFunctional role of follicular helper T cells in chronic lymphocytic leukemia
Fajardo Despaigne, J. E., & Fajardo Despaigne, J. E. (2020) · Mspace (University of Manitoba)
Estudio de la expresión del lncRNA MALAT1 y su relevancia biomédica en linfomas de célula B pequeña
Fernández Garnacho, E. M. (2023) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Wierz, M. (2020) · theses.fr (ABES) · doi:10.70675/80454a47z3b6bz4b8bza0c3z684d69f087b3 · Cited by 1
PI3Kδ in Cancer: From Biological Functions to Therapeutic Opportunities
Godugu, D., & Agarwal, S. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.109722
Lee, N., & Kim, Y. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1948652
Metadata
- Authors
- Hanna, B. S., Roessner, P. M., Scheffold, A., Jebaraj, B. M. C., Demerdash, Y., Öztürk, S., Lichter, P., Stilgenbauer, S., & Seiffert, M.
- Affiliations
- German Cancer Research Center (DE)
- University Hospital Ulm (DE)
- Corresponding author
- Hanna, Bola S.
- Seiffert, Martina
- ORCID
- Venue
- Leukemia
- Published
- 2018-12-20
- Volume
- 33
- Issue
- 6
- Pages
- 1427-1438
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2904653639
- Cited by
- 55
- References
- 60
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 10 · 2022: 5 · 2021: 14 · 2020: 16 · 2019: 5
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (SFB1074 project B1)
- Bundesministerium für Bildung und Forschung (Precise, FIRE-CLL, Fire-CLL)
- José Carreras Leukämie-Stiftung (R14/23)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- PI3Kδ inhibition, idelalisib, chronic lymphocytic leukemia, regulatory T cells, CD8+ T cell activation, effector T cell differentiation, T cell receptor signaling, immunomodulation, B cell receptor signaling, combination therapy
- MeSH terms
- Animals, Antineoplastic Agents, Cell Differentiation, Female, Humans, Lymphocyte Activation, Mice, Inbred C57BL, Purines, Tumor Cells, Cultured, Signal Transduction, Leukemia, Lymphocytic, Chronic, B-Cell, CD8-Positive T-Lymphocytes, T-Lymphocytes, Regulatory, Mice, Quinazolinones, Class I Phosphatidylinositol 3-Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.